- Investing.com
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.

Metrics to compare | BLLN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLLNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 1,269.4x | −3.1x | −0.5x | |
PEG Ratio | 12.61 | −0.23 | 0.00 | |
Price / Book | 7.7x | 2.6x | 2.6x | |
Price / LTM Sales | 12.1x | 1.0x | 3.2x | |
Upside (Analyst Target) | 48.9% | 41.7% | 45.7% | |
Fair Value Upside | Unlock | 38.1% | 4.8% | Unlock |